Published Paper Details:

AIM AND OBJECTIVE: To evaluate the safety and efficacy of galcanezumab in chronic migraine. METHODS: An observational study of galcanezumab (LY2951742) in patients with chronic migraine. Eligible patients 18-65 years of age (n=60) with chronic migraine were given monthly injection of placebo, galcanezumab 120 mg or 240 mg. The mean change in monthly migraine headache days was the primary outcome. As safety outcomes, the percentages of patients who reported at least one adverse event, at least one significant adverse event, or who dropped out of the study where considered. RESULT: Both galcanezumab dose group demonstrated greater overall mean reduction in the number of monthly MHDs compared to placebo. There was a significant reduction in the proportion of remaining MHDs with nausea and vomiting for episodic and chronic migraine studies and with photophobia and phonophobia for episodic migraine studies.Galcanezumab was also found to be more effective in all important secondary outcomes. In terms of safety, the majority of adverse events were mild to moderate, with low dropout rates and significant adverse events. CONCLUSION: We conclude that both doses of galcanezumab is an efficacious and well tolerated preventive treatment for migraine and were superior to control group in reducing number of monthly MHDs.